^
    Back
    Association details:
    Biomarker:ATM mutation
    Cancer:Prostate Cancer
    Drug:Bavencio (avelumab) (PD-L1 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    New
    Source:
    ESMO 2021
    Title:

    631P - Safety and efficacy of avelumab plus carboplatin in patients with metastatic castration resistant prostate cancer in an open-label phase Ib study

    Published date:
    09/13/2021
    Excerpt:
    These 2 responders had both a known HRD deleterious mutation (one BRCA2, one ATM). Disease control rate was 69.2% (18/26). Median radiographic PFS was 6.78 months (95% CI 4.28-9.01) and median OS 10.56 months (95% CI 6.68-NR)...Avelumab plus carboplatin has an acceptable safety profile. Overall clinical benefit was seen in almost 70% of patients and was associated with a prolonged OS given the heavily pretreated population.
    Secondary therapy:
    carboplatin
    Evidence Level:
    Sensitive: C4 – Case Studies
    Source:
    Br J Cancer
    Title:

    Safety and efficacy of avelumab plus carboplatin in patients with metastatic castration-resistant prostate cancer in an open-label Phase Ib study

    Published date:
    10/26/2022
    Excerpt:
    Safety and efficacy avelumab plus carboplatin was investigated in a single-arm Phase Ib study in mCRPC...Two of these responders had a known DDR alteration (one BRCA2, one ATM).
    DOI:
    https://doi.org/10.1038/s41416-022-01991-4